Immunogenic comparison of chimeric adenovirus 5/35 vector carrying optimized human immunodeficiency virus clade C genes and various promoters

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Shoji, Masaki ^a,b   Yoshizaki, Shinji ^a   Mizuguchi, Hiroyuki ^b,c   Okuda, Kenji ^d   Shimada, Masaru ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

^d Fukushimura Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; HYBRID PROTEIN; VIRUS ENVELOPE PROTEIN; REV PROTEIN;

ADENOVIRUS 5; ARTICLE; CLADISTICS; CODON USAGE; CONTROLLED STUDY; DRUG EFFICACY; ENVELOPE GENE; GENE CASSETTE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; NONHUMAN; PHASE 2 CLINICAL TRIAL; PROMOTER REGION; PROTEIN EXPRESSION; ANIMAL; CELL LINE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE VECTOR; GENETICS; HELA CELL; HUMAN ADENOVIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; MOUSE; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADENOVIRIDAE; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MUS;

ADENOVIRUSES, HUMAN; ANIMALS; BLOTTING, WESTERN; CELL LINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE PRODUCTS, GAG; GENE PRODUCTS, REV; GENETIC VECTORS; HELA CELLS; HIV-1; HUMANS; MICE; PROMOTER REGIONS, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84855992930     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030302     Document Type: Article

References (48)

1. Moore JP, Klasse PJ, Dolan MJ, Ahuja SK, (2008) AIDS/HIV. A STEP into darkness or light? Science 320: 753-755.
2. Sekaly RP, (2008) The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J Exp Med 205: 7-12.
3. Hemelaar J, Gouws E, Ghys PD, Osmanov S, (2006) Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 20: W13-23.
4. Lole KS, Bollinger RC, Paranjape RS, Gadkari D, Kulkarni SS, et al. (1999) Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. J Virol 73: 152-160.
5. Zhang L, Chen Z, Cao Y, Yu J, Li G, et al. (2004) Molecular characterization of human immunodeficiency virus type 1 and hepatitis C virus in paid blood donors and injection drug users in china. J Virol 78: 13591-13599.
6. van Harmelen J, Williamson C, Kim B, Morris L, Carr J, et al. (2001) Characterization of full-length HIV type 1 subtype C sequences from South Africa. AIDS Res Hum Retroviruses 17: 1527-1531.
7. Mizuguchi H, Hayakawa T, (2002) Adenovirus vectors containing chimeric type 5 and type 35 fiber proteins exhibit altered and expanded tropism and increase the size limit of foreign genes. Gene 285: 69-77.
8. Gaggar A, Shayakhmetov DM, Lieber A, (2003) CD46 is a cellular receptor for group B adenoviruses. Nat Med 9: 1408-1412.
9. Xin KQ, Jounai N, Someya K, Honma K, Mizuguchi H, et al. (2005) Prime-boost vaccination with plasmid DNA and a chimeric adenovirus type 5 vector with type 35 fiber induces protective immunity against HIV. Gene Ther 12: 1769-1777.
10. Gao F, Li Y, Decker JM, Peyerl FW, Bibollet-Ruche F, et al. (2003) Codon usage optimization of HIV type 1 subtype C gag, pol, env, and nef genes: in vitro expression and immune responses in DNA-vaccinated mice. AIDS Res Hum Retroviruses 19: 817-823.
11. Shinoda K, Xin KQ, Jounai N, Kojima Y, Tamura Y, et al. (2004) Polygene DNA vaccine induces a high level of protective effect against HIV-vaccinia virus challenge in mice. Vaccine 22: 3676-3690.
12. Xu ZL, Mizuguchi H, Ishii-Watabe A, Uchida E, Mayumi T, et al. (2001) Optimization of transcriptional regulatory elements for constructing plasmid vectors. Gene 272: 149-156.
13. Pelletier J, Sonenberg N, (1988) Internal initiation of translation of eukaryotic mRNA directed by a sequence derived from poliovirus RNA. Nature 334: 320-325.
14. Molla A, Jang SK, Paul AV, Reuer Q, Wimmer E, (1992) Cardioviral internal ribosomal entry site is functional in a genetically engineered dicistronic poliovirus. Nature 356: 255-257.
15. Mountford PS, Smith AG, (1995) Internal ribosome entry sites and dicistronic RNAs in mammalian transgenesis. Trends Genet 11: 179-184.
16. Mizuguchi H, Xu Z, Ishii-Watabe A, Uchida E, Hayakawa T, (2000) IRES-dependent second gene expression is significantly lower than cap-dependent first gene expression in a bicistronic vector. Mol Ther 1: 376-382.
17. Fang J, Qian JJ, Yi S, Harding TC, Tu GH, et al. (2005) Stable antibody expression at therapeutic levels using the 2A peptide. Nat Biotechnol 23: 584-590.
18. Fang J, Yi S, Simmons A, Tu GH, Nguyen M, et al. (2007) An antibody delivery system for regulated expression of therapeutic levels of monoclonal antibodies in vivo. Mol Ther 15: 1153-1159.
19. Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, et al. (2006) HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107: 4781-4789.
20. Kannanganat S, Kapogiannis BG, Ibegbu C, Chennareddi L, Goepfert P, et al. (2007) Human immunodeficiency virus type 1 controllers but not noncontrollers maintain CD4 T cells coexpressing three cytokines. J Virol 81: 12071-12076.
21. Barouch DH, (2008) Challenges in the development of an HIV-1 vaccine. Nature 455: 613-619.
22. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB, (1994) Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 68: 6103-6110.
23. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, et al. (1994) Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 68: 4650-4655.
24. Pantaleo G, Demarest JF, Soudeyns H, Graziosi C, Denis F, et al. (1994) Major expansion of CD8+ T cells with a predominant V beta usage during the primary immune response to HIV. Nature 370: 463-467.
25. Kiepiela P, Leslie AJ, Honeyborne I, Ramduth D, Thobakgale C, et al. (2004) Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature 432: 769-775.
26. Kiepiela P, Ngumbela K, Thobakgale C, Ramduth D, Honeyborne I, et al. (2007) CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 13: 46-53.
27. Matano T, Kobayashi M, Igarashi H, Takeda A, Nakamura H, et al. (2004) Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial. J Exp Med 199: 1709-1718.
28. Seder RA, Darrah PA, Roederer M, (2008) T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 8: 247-258.
29. Betts MR, Brenchley JM, Price DA, De Rosa SC, Douek DC, et al. (2003) Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 281: 65-78.
30. Clay TM, Hobeika AC, Mosca PJ, Lyerly HK, Morse MA, (2001) Assays for monitoring cellular immune responses to active immunotherapy of cancer. Clin Cancer Res 7: 1127-1135.
31. Whiteside TL, Zhao Y, Tsukishiro T, Elder EM, Gooding W, et al. (2003) Enzyme-linked immunospot, cytokine flow cytometry, and tetramers in the detection of T-cell responses to a dendritic cell-based multipeptide vaccine in patients with melanoma. Clin Cancer Res 9: 641-649.
32. Szymczak AL, Workman CJ, Wang Y, Vignali KM, Dilioglou S, et al. (2004) Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector. Nat Biotechnol 22: 589-594.
33. Ryan MD, King AM, Thomas GP, (1991) Cleavage of foot-and-mouth disease virus polyprotein is mediated by residues located within a 19 amino acid sequence. J Gen Virol 72 (Pt 11): 2727-2732.
34. Shiver JW, Fu TM, Chen L, Casimiro DR, Davies ME, et al. (2002) Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415: 331-335.
35. Churchyard GJ, Morgan C, Adams E, Hural J, Graham BS, et al. (2011) A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204). PLoS One 6: e21225.
36. Wadell G, (1984) Molecular epidemiology of human adenoviruses. Curr Top Microbiol Immunol 110: 191-220.
37. Kostense S, Koudstaal W, Sprangers M, Weverling GJ, Penders G, et al. (2004) Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. AIDS 18: 1213-1216.
38. Barouch DH, Pau MG, Custers JH, Koudstaal W, Kostense S, et al. (2004) Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol 172: 6290-6297.
39. Shimada M, Wang HB, Kondo A, Xu XP, Yoshida A, et al. (2009) Effect of therapeutic immunization using Ad5/35 and MVA vectors on SIV infection of rhesus monkeys undergoing antiretroviral therapy. Gene Ther 16: 218-228.
40. Wang HB, Kondo A, Yoshida A, Yoshizaki S, Abe S, et al. (2010) Partial protection against SIV challenge by vaccination of adenovirus and MVA vectors in rhesus monkeys. Gene Ther 17: 4-13.
41. Seshidhar Reddy P, Ganesh S, Limbach MP, Brann T, Pinkstaff A, et al. (2003) Development of adenovirus serotype 35 as a gene transfer vector. Virology 311: 384-393.
42. Kozak M, (1986) Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes. Cell 44: 283-292.
43. Mizuguchi H, Kay MA, (1999) A simple method for constructing E1- and E1/E4-deleted recombinant adenoviral vectors. Hum Gene Ther 10: 2013-2017.
44. Niwa H, Yamamura K, Miyazaki J, (1991) Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108: 193-199.
45. Maizel JV Jr, White DO, Scharff MD, (1968) The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. Virology 36: 115-125.
46. Kanegae Y, Makimura M, Saito I, (1994) A simple and efficient method for purification of infectious recombinant adenovirus. Jpn J Med Sci Biol 47: 157-166.
47. Abe S, Okuda K, Ura T, Kondo A, Yoshida A, et al. (2009) Adenovirus type 5 with modified hexons induces robust transgene-specific immune responses in mice with pre-existing immunity against adenovirus type 5. J Gene Med 11: 570-579.
48. Xin KQ, Sekimoto Y, Takahashi T, Mizuguchi H, Ichino M, et al. (2007) Chimeric adenovirus 5/35 vector containing the clade C HIV gag gene induces a cross-reactive immune response against HIV. Vaccine 25: 3809-3815.